CardiAQ allocates $6.5M for mitral valve implantation research

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon
In order to clinically investigate its Transcatheter Mitral Valve Implantation (TMVI) system, CardiAQ Valve Technologies has doled out $6.5 million for research.

According to the Winchester, Mass.-based company, funding was led by Rob Michiels and incorporates conversion of all previous debt to study the TMVI technology. The system is used as a non-surgical alternative for patients with functional mitral regurgitation and who are too sick to undergo surgery, according to CardiAQ.